Cg-0416

Phase 1

HHongKong Curegene Innovation Co., Limited

Cg-0416 is one of 4 therapeutic programs targeting Overweight and Obesity. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Overweight and ObesityNot yet recruiting

Overweight and ObesityPhase 1

Not yet recruiting

Competition

Competitive Landscape

6 competitors in Overweight and Obesity

#DrugCompanyPhaseTrials

ATR-258

AAtrogi AB

Phase 2

1 2

LAE102 IV

LLaekna Limited

Phase 1

1 3

Cg-0416

HHongKong Curegene Innovation Co., Limited

Phase 1

1 4

AZD9550

AstraZeneca

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Not yet recruiting

Overweight and Obesity

NCT07724431

Clinical

Trials by Indication[1]

Overweight and Obesity1 trial

A Phase 1, Double-blind, Randomized Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Single Dose and Multiple Doses of CG-0416 in Healthy Participants.

Not yet recruiting·HHongKong Curegene Innovation Co., Limited·Phase 1·NCT07724431·64 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cg-0416. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Cg-0416. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — HongKong Curegene Innovation Co., Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: HHongKong Curegene Innovation Co., Limited

Cg-0416

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Overweight and Obesity1 trial

References

Drug Info

Quick Facts

Related News